Structure-Activity Relationship Study to Develop Peptide Amphiphiles as Species-Specific Antimicrobials

Area of Science:

• Biomaterials Science
• Nanotechnology
• Microbiology

Background:

• Antimicrobial peptide amphiphiles (PAs) are versatile molecules with potential applications in disrupting bacterial membranes and serving as drug nanocarriers.
• The development of novel antibacterial agents is crucial due to rising antimicrobial resistance.

Purpose of the Study:

• To establish supramolecular structure-activity relationships for 33 PAs.
• To investigate the antibacterial activity and mechanisms of PA nanostructures against various bacterial strains.
• To evaluate the in vitro and in vivo efficacy and toxicity of promising PA candidates.

Main Methods:

• Preparation and characterization of 33 peptide amphiphiles (PAs).
• Assessment of nanostructure morphology and antimicrobial activity against Gram-positive (e.g., Staphylococcus aureus) and Gram-negative (e.g., Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii) bacteria.
• Principal component analysis (PCA) to identify key structure-activity drivers (zeta potential, LogP).
• Mechanistic studies including membrane permeability, depolarization, zeta potential, and integrity assays.
• In vitro mammalian cell toxicity assessments.
• In vivo therapeutic efficacy studies using wax moth larvae.

Main Results:

• Identified key contributors to PA activity: zeta potential for S. aureus and partition coefficient (LogP) for Gram-negative bacteria (P. aeruginosa > E. coli > A. baumannii).
• Elucidated mechanisms of action involving bacterial membrane disruption.
• Demonstrated low toxicity against mammalian cells for effective candidates.
• Confirmed therapeutic efficacy in an in vivo model.

Conclusions:

• Cationic PA nanostructures represent a promising platform for developing novel nanoantibacterials.
• Supramolecular structure significantly influences antibacterial activity, offering a rational design approach.
• The findings support the potential of PAs as an alternative to conventional antibiotics.